JP2002000716A - Covering material for granulation - Google Patents
Covering material for granulationInfo
- Publication number
- JP2002000716A JP2002000716A JP2000186646A JP2000186646A JP2002000716A JP 2002000716 A JP2002000716 A JP 2002000716A JP 2000186646 A JP2000186646 A JP 2000186646A JP 2000186646 A JP2000186646 A JP 2000186646A JP 2002000716 A JP2002000716 A JP 2002000716A
- Authority
- JP
- Japan
- Prior art keywords
- granulation
- gelatin
- matrix
- collagen
- voids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003179 granulation Effects 0.000 title claims abstract description 62
- 238000005469 granulation Methods 0.000 title claims abstract description 62
- 239000000463 material Substances 0.000 title claims abstract description 46
- 239000011159 matrix material Substances 0.000 claims abstract description 71
- 108010010803 Gelatin Proteins 0.000 claims abstract description 52
- 229920000159 gelatin Polymers 0.000 claims abstract description 51
- 239000008273 gelatin Substances 0.000 claims abstract description 51
- 235000019322 gelatine Nutrition 0.000 claims abstract description 51
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 51
- 239000011800 void material Substances 0.000 claims abstract description 43
- 229920001436 collagen Polymers 0.000 claims abstract description 40
- 108010035532 Collagen Proteins 0.000 claims abstract description 34
- 102000008186 Collagen Human genes 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 239000011248 coating agent Substances 0.000 claims description 19
- 238000000576 coating method Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 239000004626 polylactic acid Substances 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 5
- 239000004633 polyglycolic acid Substances 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 27
- 210000000416 exudates and transudate Anatomy 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 16
- 230000007547 defect Effects 0.000 description 15
- 238000005187 foaming Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000000306 component Substances 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 210000000601 blood cell Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 208000025865 Ulcer Diseases 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000017423 tissue regeneration Effects 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000004210 Pressure Ulcer Diseases 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 206010056340 Diabetic ulcer Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000003929 acidic solution Substances 0.000 description 3
- 108010045569 atelocollagen Proteins 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000009772 tissue formation Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229920006268 silicone film Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102100028175 Abasic site processing protein HMCES Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001006387 Homo sapiens Abasic site processing protein HMCES Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、糖尿病性潰瘍、褥
瘡などの難治性潰瘍による組織欠損の再生を目的として
使用される肉芽造成用被覆材料に関するものである。更
に詳しくは、毛細血管、細胞を誘引することにより肉芽
造成を促進するための大空隙部を有し生体組織を速やか
に再構築させる生体分解性材料のマトリックスからなる
肉芽造成用被覆材料に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a coating material for granulation, which is used to regenerate tissue defects caused by intractable ulcers such as diabetic ulcer and pressure ulcer. More specifically, the present invention relates to a coating material for granulation, comprising a matrix of a biodegradable material having a large void portion for promoting granulation by attracting capillaries and cells to rapidly reconstruct a living tissue.
【0002】[0002]
【従来の技術】従来、糖尿病性潰瘍、褥瘡などの難治性
潰瘍の治療には、損傷面の外部からの保護、表皮化を促
すような湿潤環境の維持、表皮化そのものを促進する薬
理作用、肉芽造成などを目的として、多くの薬剤が用い
られてきた。難治性の潰瘍の治癒が困難なのは、潰瘍の
損傷表面に、治癒に必要な表皮化または治療に必要な皮
膚移植の母床となる組織の土台(肉芽と呼ばれる組織)
がないことが主因である。2. Description of the Related Art Conventionally, treatment of intractable ulcers such as diabetic ulcers and pressure ulcers involves protecting the injured surface from the outside, maintaining a moist environment that promotes epidermis, and a pharmacological action that promotes epidermis itself. Many drugs have been used for granulation and the like. The difficulty of healing intractable ulcers is that the damaged ulcer surface is the base of the tissue that becomes the epidermis necessary for healing or the base for skin transplantation needed for treatment (tissue called granulation)
The main reason is that there is no.
【0003】現在、肉芽造成を主目的と謳っている薬
剤、被覆材は少数であるが存在する。しかし薬剤を用い
た場合、実際には肉芽が生ずるまでに頻回に損傷部に塗
布する必要があるほか、出来上がった肉芽の表面が粒状
を呈すなどして必ずしも表皮化や皮膚移植に適した母床
になるとは限らない。At present, there are a small number of drugs and coating materials that claim that the main purpose is granulation. However, when a drug is used, it is necessary to apply it frequently to the damaged area before granulation actually occurs. In addition, the surface of the formed granulation becomes granular, so that the mother is not necessarily suitable for epidermis or skin transplantation. Not necessarily the floor.
【0004】また、被覆材では、創面を完全に閉鎖して
しまうので、滲出液が貯留しやすく、貯留した浸出液に
細菌が移行して感染の蔓延の原因となってしまってい
た。更に、浸出液の貯留は少なく、創面観察も可能なタ
イプの被覆材も存在するが、生分解性ではないので一定
期間後に除去するか、自然に排出されることを期待する
こととなり、管理上・手間上の問題が残る。特にいった
ん肉芽が被覆材の繊維中に絡んだ後に除去することにな
れば、患者に著しい疼痛をもたらす可能性もある。[0004] In addition, in the case of a dressing material, since the wound surface is completely closed, exudate is easily stored, and bacteria are transferred to the stored exudate, causing infection to spread. Furthermore, there is a small amount of leachate stored, and there is a type of dressing that allows observation of the wound surface.However, since it is not biodegradable, it is expected that it will be removed after a certain period of time, or that it will be discharged naturally. The troubles remain. It can also cause significant pain to the patient, especially once the granulation has to be removed after it has become entangled in the fibers of the dressing.
【0005】最近、コラーゲン製の真皮欠損用グラフト
(いわゆる「人工真皮」)をこれら難治性の潰瘍に適用
し、めざましい効果があることが見出されてきている
(形成外科、第39巻第8号、P779-787(1996);皮膚、
第38巻第3号、P386-389(1996)。「人工真皮」の組織
再生能力を難治性潰瘍の肉芽造成に役立てようという試
みである。しかしながら「人工真皮」をそのまま適用す
ると滲出液が貯留するなどの欠点があり、最近では細か
くちぎって詰める、ドレーン孔などの穴またはスリット
を開けるなどの工夫により滲出液の排液を行っている
(形成外科、第39巻第8号、P779-787(1996)。しか
し、細かくちぎるのには手間がかかり、。また、「人工
真皮」はコラーゲン製のスポンジ上にシリコーン製の膜
を有する場合が多く、ドレーン孔を有する場合、ドレー
ン孔の部分に生じた肉芽はシリコーン膜を巻き込んで固
着を起こし、場合によってはシリコーン膜除去のための
再手術を必要とする。また、コラーゲンを使用する「人
工真皮」は原料が高価であることに加え、物理・化学的
処理により変性・分解しやすいことから工程、バリデー
ションが繁雑となりコスト高になる可能性があるため、
例えば褥瘡などの治療に頻繁に使用するのは経済的に困
難と考えられる。Recently, a dermis defect graft made of collagen (so-called “artificial dermis”) has been applied to these intractable ulcers and has been found to have remarkable effects (plastic surgery, Vol. 39, No. 8). No., P779-787 (1996); skin,
Vol. 38, No. 3, P386-389 (1996). This is an attempt to use the tissue regeneration ability of the "artificial dermis" for granulation of intractable ulcers. However, if the "artificial dermis" is applied as it is, there is a drawback such as accumulation of exudate, and recently, exudate is drained by means such as finely tearing and packing, opening holes such as drain holes or slits ( Plastic Surgery, Vol. 39, No. 8, P779-787 (1996) However, it takes time and effort to cut fine, and "artificial dermis" sometimes has a silicone membrane on a collagen sponge. In many cases, when there is a drain hole, the granulation generated in the drain hole portion involves the silicone film and causes sticking, and in some cases, requires reoperation for removing the silicone film. In addition to the expensive raw materials, dermis is easily denatured and decomposed by physical and chemical treatments. Because there is,
Frequent use in the treatment of, for example, pressure ulcers may be economically difficult.
【0006】[0006]
【発明が解決しようとする課題】上記の様に従来の難治
性潰瘍の治療用被覆材では、滲出液が貯留し、貯留した
滲出液に細菌が移行して感染が蔓延する原因となった
り、適用した被覆材を一定期間後に除去したりしなけれ
ばならなかった。As described above, in the conventional dressing for treating intractable ulcers, the exudate accumulates, and bacteria are transferred to the accumulated exudate, causing infection to spread. The applied coating had to be removed after a certain period of time.
【0007】従って、糖尿病性潰瘍、褥瘡などの難治性
潰瘍の治療に用いる被覆材であっって、滲出液を貯留さ
せずに、損傷面に肉芽を造成し、追加処置で目的達成後
の除去を行うことなく肉芽を造成でき、低コストで治療
可能な材で、治療に有効な物質を患者自身から得て有効
活用できる被覆材を提供することを目的とする。[0007] Accordingly, the present invention is a dressing for treating intractable ulcers such as diabetic ulcers and pressure ulcers, wherein granules are formed on the damaged surface without accumulating exudate and removed after the objective is achieved by additional treatment. It is an object of the present invention to provide a coating material that can form a granulation without performing the treatment, can be treated at low cost, and can obtain a substance effective for treatment from the patient himself and can utilize it effectively.
【0008】[0008]
【課題を解決するための手段】上述した課題を解決し目
的を達成するために本発明では、肉芽造成を目的とする
大空隙部を有する、生体分解性材料からなるスポンジ状
・フォーム状など多数の小空隙部を持ったマトリックス
を利用し、これを損傷表面に貼付することにより、損傷
表面側に開口した大空隙部により滲出液の吸収を促進し
つつ大小の空隙部に効率よく自己体液(滲出液、血液を
含む)中の必要物質を吸着して利用することによって、
大空隙部中に積極的に毛細血管・細胞を誘引して肉芽造
成を促し、その結果波及的に小空隙に毛細血管・細胞を
伸展させて肉芽生体組織を速やかに再構築させることに
より目的を達成した。According to the present invention, there is provided a sponge-like or foam-like material made of a biodegradable material having a large void for the purpose of granulation. By using a matrix with small voids and attaching it to the damaged surface, the large voids open to the damaged surface promote the absorption of exudate while efficiently removing the body fluid from the large and small voids. (Including exudates and blood)
By actively attracting capillaries and cells into the large voids to promote the formation of granulation, as a result, the capillaries and cells are extended into the small voids to quickly reconstruct the granulation biological tissue. Achieved.
【0009】具体的には、本発明は大空隙部と、大空隙
部数に比して多数の小空隙部を有する生体分解性材料で
構成される多孔質マトリックスからなる肉芽造成用被覆
材料を提供するものである。また本発明は、生体分解性
材料からなる多孔質マトリックスの大空隙部が、スリッ
ト状、四角柱、円柱または楕円柱の形状を有し、特にス
リット状の大空隙部は少なくとも多孔質マトリックスの
厚さ以上の長径を有し、更に大空隙部が多孔質マトリッ
クス表面の少なくとも一方に開口部を有している肉芽造
成用被覆材料を提供するものである。更に、本発明は、
生体分解性材料からなる多孔質マトリックスの小空隙部
の径が5μm以上で多孔質マトリックスの厚さ以下であ
る肉芽造成用被覆材料を提供するものである。Specifically, the present invention provides a coating material for granulation comprising a porous matrix composed of a biodegradable material having large voids and a large number of small voids compared to the number of large voids. Is what you do. Further, the present invention provides a porous matrix made of a biodegradable material, wherein the large voids have a slit shape, a quadrangular prism, a cylindrical shape, or an elliptical cylindrical shape, and particularly the slit-like large voids have at least a thickness of the porous matrix. An object of the present invention is to provide a coating material for granulation formation, which has a longer diameter than that of the porous matrix, and further has a large void portion having an opening in at least one of the surfaces of the porous matrix. Further, the present invention provides
An object of the present invention is to provide a coating material for granulation formation, wherein the diameter of small voids in a porous matrix made of a biodegradable material is 5 μm or more and not more than the thickness of the porous matrix.
【0010】本発明はまた、生体分解性材料が、ゼラチ
ン、コラーゲン、糖類、ポリ乳酸またはポリグリコール
酸を単独または混合したものである肉芽造成用被覆材料
を提供するものである。本発明は生体分解性材料が、ゼ
ラチンとコラーゲンを混合したもので構成されている肉
芽造成用被覆材料を提供するものである。The present invention also provides a coating material for granulation, wherein the biodegradable material is a mixture of gelatin, collagen, saccharide, polylactic acid or polyglycolic acid, alone or as a mixture. The present invention provides a coating material for granulation, wherein the biodegradable material is composed of a mixture of gelatin and collagen.
【0011】[0011]
【発明の実施の形態】本発明の生体分解性材料として
は、ゼラチン、コラーゲン、糖類、ポリ乳酸またはポリ
グリコール酸を単独または混合して用いることができる
が、生体分解性のマトリックスとして最も好適なもの
は、ゼラチンである。ゼラチンの主たる成分は生体のタ
ンパク質の3分の1を占めるコラーゲンの構成アミノ酸
とほぼ同一である。従って、生体内で分解吸収されるに
あたり不都合は少ない。またゼラチンは工業的な生産に
耐えるものであり、コラーゲンに比して非常に安価に入
手できる。実際に本発明に使用されるゼラチンは、精製
ゼラチン(例えば日本薬局方収載の精製ゼラチン(いわ
ゆる局方ゼラチン))が好ましい。ゼラチンは単独で大
空隙部と小空隙部からなる異種空隙内包生分解性マトリ
ックスを構成することができる。BEST MODE FOR CARRYING OUT THE INVENTION As the biodegradable material of the present invention, gelatin, collagen, saccharide, polylactic acid or polyglycolic acid can be used alone or as a mixture. The thing is gelatin. The main components of gelatin are almost the same as the constituent amino acids of collagen, which make up one third of the protein of living organisms. Therefore, there is little inconvenience in decomposing and absorbing in vivo. In addition, gelatin can withstand industrial production and can be obtained at a very low cost as compared with collagen. Actually, the gelatin used in the present invention is preferably a purified gelatin (for example, a purified gelatin listed in the Japanese Pharmacopoeia (so-called local gelatin)). Gelatin alone can constitute a biodegradable matrix encapsulating heterogeneous voids consisting of large voids and small voids.
【0012】しかし、損傷表面で吸水して、水平方向へ
の拡張が大空隙部を埋めてしまうと効果が減少する傾向
がある。また物性的にもゼラチン単独では硬くてもろ
く、使用前に脆性破壊することもあり得る。そこで本発
明の検討では、ゼラチンにコラーゲンを混合することで
所望の物性を持つマトリックスを得た。これにより過度
の拡張は押さえられて肉芽造成の場としての大空隙部の
空隙は確保され、物性もより柔軟となる。また水分保持
性もゼラチン単独よりは向上した。物性的な変化は、棒
状高分子であるコラーゲンが骨格としての形態保持に資
するためと考えられる。しかし、コラーゲンは極めて高
価であり、ゼラチンは安価であるため、ゼラチン比が多
いほど費用対効果は高い。However, the effect tends to decrease when water is absorbed at the damaged surface and expansion in the horizontal direction fills the large void. In terms of physical properties, gelatin alone is hard and brittle, and may be brittlely broken before use. Therefore, in the study of the present invention, a matrix having desired physical properties was obtained by mixing collagen with gelatin. As a result, excessive expansion is suppressed, the voids in the large voids as a place for granulation are secured, and the physical properties become more flexible. The water retention was also improved over gelatin alone. The change in physical properties is considered to be due to the fact that collagen, which is a rod-like polymer, contributes to maintaining the form as a skeleton. However, collagen is extremely expensive and gelatin is inexpensive, so the higher the gelatin ratio, the more cost-effective.
【0013】糖類はゼラチンまたはゼラチン−コラーゲ
ン混合物の増量剤として使用できる。単糖類、二糖類で
は損傷表面に適用後比較的短時間で流出する傾向があ
り、増量効果が薄れる可能性があるので、より高分子で
ある多糖類が最適な増量の候補である。より好ましく
は、ゼラチンと親和性の高いムコ多糖類(デルマタン硫
酸、コンドロイチン硫酸、ヘパリン、ヒアルロン酸、な
ど)の利用が考えられる。ムコ多糖類とゼラチンは、コ
ンプレックスを形成しやすいので、形状保持にも好都合
である。[0013] Sugars can be used as fillers in gelatin or gelatin-collagen mixtures. Since monosaccharides and disaccharides tend to flow out in a relatively short time after application to the damaged surface, and the effect of weight increase may be weakened, polysaccharides having higher molecular weights are candidates for the optimal weight increase. More preferably, use of a mucopolysaccharide having high affinity for gelatin (dermatan sulfate, chondroitin sulfate, heparin, hyaluronic acid, etc.) can be considered. Mucopolysaccharide and gelatin are easy to form a complex, and are therefore advantageous for shape retention.
【0014】一方、ゼラチン並みの安価で入手できる生
分解性材料として、ポリ乳酸またはポリグリコール酸も
利用可能な物質である。ポリ乳酸は最近工業生産体制が
確立して安価に大量に生産できるようになった。溶液状
で発泡させて固形化が可能である。また、通常のプラス
チックと同様、ポリエチレングリコール(PEG)など
と相溶させて後処理でPEGを溶出させ多孔体を得るこ
とも可能である。On the other hand, polylactic acid or polyglycolic acid is a substance which can be used as a biodegradable material as inexpensive as gelatin. Recently, polylactic acid has been established in an industrial production system and can be mass-produced inexpensively. It can be solidified by foaming in the form of a solution. Further, similarly to ordinary plastics, it is also possible to obtain a porous body by dissolving with polyethylene glycol (PEG) or the like and eluted PEG by post-treatment.
【0015】ゼラチンまたはポリ乳酸、ポリグリコール
酸を主体とする異種空隙内包生分解性マトリックスは、
変性、分解が恐れられるコラーゲンのような慎重な取扱
いを必ずしも必要としない。必要に応じて真空熱脱水
法、乾熱法、あるいはγ線照射法、紫外線照射法、電子
線照射法、X線照射法、EOG法のいずれかの手段、また
はそのうちの任意の組合せを取ることが可能である。こ
のうちγ線照射法、EOG法は、それぞれの方法によって
ゼラチンタンパク質に分子間結合の切断、ガスの吸着な
どが起こり得るため、それぞれの処理の前にあらかじめ
加熱処理等を行って分子間の結合を架橋強化することが
望ましい。本発明による肉芽造成の効果はこれらの滅菌
処理により妨げられることはない。最終滅菌が可能なこ
とは工程数削減に有利であり、また、安全性の保証の上
でも有利と考えられる。[0015] A biodegradable matrix containing heterogeneous voids mainly composed of gelatin, polylactic acid, or polyglycolic acid,
Careful handling such as collagen which may be denatured or degraded is not always necessary. If necessary, use vacuum thermal dehydration, dry heat, γ-ray irradiation, ultraviolet irradiation, electron beam irradiation, X-ray irradiation, EOG, or any combination of these. Is possible. Among these methods, the γ-ray irradiation method and the EOG method can break intermolecular bonds and adsorb gas in the gelatin protein by each method. Is desirably cross-linked. The effect of granulation according to the present invention is not hindered by these sterilization treatments. The possibility of final sterilization is advantageous for reducing the number of steps, and is also considered to be advantageous for ensuring safety.
【0016】本発明の肉芽造成を主たる目的とする大空
隙部は、マトリックスの少なくとも一方に有する開口部
が創傷部、組織欠損部など何らかの組織修復を必要とし
た側に密着する必要がある。この大空隙開口部は、滲出
液が吸収される際に滲出液中の有用成分を吸着する。こ
のことによりそれを誘因として毛細血管や各種の細胞が
大空隙部内に遡上し、それらの成分の活動により該大空
隙部に肉芽が造成される。その大空隙は、上述の血管・
細胞の遡上を妨げない形状を有し、スリット状、または
四角柱、または円柱、楕円柱の形状が好ましい。In the large void portion of the present invention mainly intended for granulation, the opening in at least one of the matrices needs to be in close contact with a wound, a defective tissue, or the like that requires some kind of tissue repair. The large void openings adsorb useful components in the exudate when the exudate is absorbed. This causes the capillaries and various cells to run up into the large voids, and granulation is formed in the large voids by the activity of these components. The large voids are
It has a shape that does not hinder the run-up of cells, and is preferably in the form of a slit, a square pillar, a cylinder, or an ellipsoid.
【0017】この形状の中でもスリット状の形状は、損
傷表面の面積や形状に応じて任意の大きさの空隙に開閉
できるという利点を持つ。また、直線でマトリックスの
表面と裏面を結ぶ連通孔となることも好ましい状況を提
供する。すなわちスリットを開いて開口部が貫通するこ
とにより、滲出液の排液が促進されて孔側面への有用物
質などの液性成分の吸収量が増え、滲出液の貯留による
感染の危険性を低減し、創面の観察も容易となる。ただ
し少なくともマトリックスの厚さ以上の長径がないとス
リットを開いて空隙を作ることが出来ない。また、マト
リックスの表面の短径をスリットの長径が超えてしまう
と、空隙の周囲にマトリックスを維持した形で維持でき
ないので、マトリックス表面長径(マトリックス表面が
長方形の場合は長辺、円の場合は直径、楕円の場合は長
径)をスリットの長径が超えてはならない。Among these shapes, the slit-like shape has an advantage that it can be opened and closed in a gap of an arbitrary size according to the area and shape of the damaged surface. In addition, it is preferable to provide a communication hole that connects the front surface and the back surface of the matrix with a straight line. In other words, by opening the slit and penetrating the opening, drainage of exudate is promoted, absorption of liquid components such as useful substances on the side of the hole increases, and the risk of infection due to accumulation of exudate is reduced. Also, observation of the wound surface becomes easy. However, if there is no major axis at least equal to the thickness of the matrix, a slit cannot be opened to form a void. Also, if the major axis of the slit exceeds the minor axis of the surface of the matrix, the matrix cannot be maintained in the form of maintaining the matrix around the void. Therefore, the major axis of the matrix surface (long side when the matrix surface is rectangular, The major axis of the slit must not exceed the diameter, or the major axis in the case of an ellipse).
【0018】スリット形状に比して、四角柱、円柱、楕
円柱などの柱状構造は、空隙の大きさを調節できない欠
点はあるが、あらかじめ型抜きなどの方法で成型品を作
るのが容易である利点を有する。スリット空隙と同様直
線でマトリックスの表面と裏面を結ぶ連通孔の形状をと
るとさらに有利である。柱状構造はテーパー形状になっ
ていても良い。この場合、目視による滲出液の透過状況
から、平行孔>下面が大きいテーパー孔>上面が大きい
テーパー孔、の順に有利である。柱状構造の大空隙部の
場合、何れの形状においても径又は辺が1mm以下である
と、滲出液や血液成分が孔部に凝固しやすくなり効果的
な結果が得られにくい。また、径又は辺が20mm以上で
あると、孔が連通している場合は肉芽造成できる大空隙
部とならず、単なる開放状態の損傷表面と同様である。As compared with the slit shape, the columnar structure such as a square column, a circular column, and an elliptical column has a drawback that the size of the gap cannot be adjusted, but it is easy to make a molded product by a method such as die cutting in advance. It has certain advantages. It is further advantageous to take the shape of the communication hole connecting the front surface and the back surface of the matrix with a straight line like the slit gap. The columnar structure may be tapered. In this case, it is advantageous in the order of parallel holes> a tapered hole having a large lower surface> a tapered hole having a large upper surface from the permeation state of the exudate visually. In the case of a large void portion having a columnar structure, if the diameter or the side is 1 mm or less in any shape, the exudate and blood components easily coagulate in the pore portion, and it is difficult to obtain an effective result. When the diameter or the side is 20 mm or more, when the pores communicate with each other, it does not become a large void portion in which granulation can be formed, and is similar to a mere open damaged surface.
【0019】何れのケースも、孔径は小さければ(スリ
ットの場合は開閉状態が小)毛細管現象、大きければ
(スリットの場合は開閉状態が大)孔の周囲のマトリッ
クスの小空隙への吸収などに補助されて血管・細胞が遡
上し肉芽が造成される。これら大空隙部については、前
記条件を満たすものであれば、必ずしも同一形状・大き
さである必要はないが、まちまちの形状をしている場合
には、形成される肉芽に不均一さをもたらす。その場
合、表皮化や移植皮膚の生着に部位による不均一を生ず
る可能性があるため、まちまちの形状はあまり推奨でき
ない。In each case, if the hole diameter is small (open / closed state is small in the case of a slit), the capillary phenomenon is performed, and if the hole diameter is large (open / closed state is large in the case of a slit), absorption into a small void of a matrix around the hole is performed. With the assistance, blood vessels and cells run up and granulation is formed. These large voids do not necessarily have to have the same shape and size as long as they satisfy the above conditions, but if they have different shapes, they will cause unevenness to be formed in the granulation. . In that case, the shape may not be very recommended because there is a possibility that the skin becomes uneven or the grafted skin engrafts depending on the site.
【0020】これらの大空隙部は、小空隙部を有するマ
トリックス体を作製後に、例えばスキングラフトメッシ
ャー等の機械的装置によってスリット状に穿孔される。
このメッシャーはスリット形状を得るには非常に有利で
あり、マトリックスを作製後であれば、どのようなタイ
ミングでも使用可能である。These large voids are formed into slits by a mechanical device such as a skin graft mesher after producing a matrix body having small voids.
This mesher is very advantageous for obtaining a slit shape, and can be used at any timing after the matrix is prepared.
【0021】またこれらの大空隙部は、小空隙部を有す
るマトリックス体を作製前に、該大空隙部の形を有する
型に流し込まれることにより各種形態の柱状構造に成型
されうる。この方法は、スリットでない大空隙部(円柱
形など)を作製するのに有利である。These large voids can be formed into various types of columnar structures by pouring them into a mold having the shape of the large voids before preparing a matrix body having the small voids. This method is advantageous for producing large voids (such as cylinders) that are not slits.
【0022】小空隙は円形、楕円形、およびその変形の
形状を含む連続した、または独立した気泡状の形状であ
って、少なくとも大空隙を下回る径を持っていれば良
い。その役割はあくまで副次的であって、前述のように
大空隙部の内側の壁の部分に表出して通過する滲出液や
血液成分中の有用物質を吸着・吸収することにより大空
隙部に血管・細胞が遡上し易い環境を出現させる。その
空孔径は少なくとも前述の大空隙を下回る径を持てば良
いと考えられるが、より好ましくは、血球成分が通過で
きる大きさ以上、マトリックスの厚さを下回る大きさで
あればよい。上記範囲を満たすものであれば、小空隙の
孔径は均一である必要はない。The small gap may have a continuous or independent bubble shape including a circular shape, an elliptical shape, and a deformed shape thereof, and may have a diameter at least smaller than that of the large gap. Its role is secondary to the last, and as described above, it absorbs and absorbs useful substances in exudates and blood components that are exposed to and pass through the inner wall of the large void, and Create an environment where blood vessels and cells can easily migrate. It is considered that the pore diameter should be at least smaller than the above-mentioned large void, but more preferably, the pore diameter should be at least a size that allows blood cell components to pass through and less than the thickness of the matrix. As long as the above range is satisfied, the pore size of the small void does not need to be uniform.
【0023】一方、小空隙が全くないマトリックスで
は、大空隙壁面からの滲出液中の成分吸着は起こらない
ため所期の効果は得られない。この小空隙は攪拌および
/または凍結乾燥の手段によって得られたスポンジ状、
フォーム状構造のものが好ましい。攪拌には、機械的に
発泡させる装置を使用することを含む。攪拌時は攪拌対
象となる生分解性の材料の主に粘度の性質により、攪拌
方法が適宜選択される。On the other hand, in a matrix having no small voids, the intended effect cannot be obtained because the components in the exudate do not adsorb from the walls of the large voids. The small voids are spongy, obtained by means of stirring and / or lyophilization,
Foam-like structures are preferred. Agitation involves the use of mechanical foaming equipment. At the time of stirring, a stirring method is appropriately selected mainly depending on the viscosity properties of the biodegradable material to be stirred.
【0024】一方、凍結乾燥は液状の素材を固形化する
ための常套手段であり、凍結した液状の素材中の氷の結
晶を昇華させて小空隙たる空間を得るため、小空隙の孔
径は氷の結晶の成長の度合いに左右される。ただし今回
の発明では、結晶の成長度合いを左右する凍結乾燥工程
中の凍結工程による小空隙のばらつきは肉芽造成に影響
を与えておらず、従って、凍結乾燥は通常の方法で十分
可能であり詳細な設定を敢えて行う必要はない。On the other hand, freeze-drying is a conventional means for solidifying a liquid material. In order to sublimate ice crystals in the frozen liquid material to obtain a space as a small space, the pore size of the small space is ice. Depends on the degree of crystal growth. However, in the present invention, the variation of small voids due to the freezing step during the freeze-drying step, which affects the degree of crystal growth, does not affect granulation, and therefore, freeze-drying can be sufficiently performed by a normal method. There is no need to dare to make any settings.
【0025】本発明の異種空隙内包生分解性マトリック
スはその片面に小空隙を有さないフィルム状の部分を有
する、あるいは小空隙の大きさが該フイルム状の面と反
対面になるに従い徐々に大きくなる傾斜性の形状を有す
る構造を持つこともある。これは特に生体分解性マトリ
ックスの材質が水分保持性が低い時に水分を逃がさない
ために有効な手段である。最終的にマトリックスが分解
吸収されて自己組織のみになることを妨げないために、
このフイルムまたは少数の孔のみを有する層は今回の発
明品と同一成分の生分解性材料であることが望ましい。The biodegradable matrix encapsulating different kinds of voids of the present invention has a film-like portion having no small voids on one surface thereof, or gradually becomes smaller as the size of the small voids becomes opposite to the film-like surface. It may have a structure with a sloped shape that increases. This is an effective means for preventing the escape of water, particularly when the material of the biodegradable matrix has low water retention. In order not to prevent the matrix from eventually being degraded and absorbed and become only self-organized,
The film or the layer having only a few holes is desirably a biodegradable material having the same components as those of the present invention.
【0026】[0026]
【実施例】以下、実施例に基づいて本発明を更に詳細に
説明する。 (実施例1) 異種空隙内包コラーゲン含有ゼラチンマトリックスの作
製 ゼラチン−コラーゲン溶液の調製 リン酸緩衝液に精製ゼラチン粉末(ナカライテスク製)
を溶解し5w/v%ゼラチン溶液を調製した。1w/v%とな
るように調製したアテロコラーゲン(株式会社高研製)
の0.1%酸性溶液を、室温下でRO水および水酸化ナ
トリウムを用いて最終濃度0.5w/v% 、pH7〜7.
5に調製し、上記で調製したゼラチン溶液を重量比5:
1の比で混合し、均一に分散してゼラチン−コラーゲン
溶液を得た。 異種空隙内包マトリックス<400-200タイプ>の作製 で調製したゼラチン−コラ−ゲン溶液を型あたりゼラ
チン:400mg、コラーゲン:200mgとなるよう
に11cm×11cmのアルミ製の型に流し込み、真空凍結
乾燥して小空隙を有するマトリックスを得た。得られた
マトリックスを180℃、1時間の乾熱処理を行うこと
により架橋を導入した。該マトリックスにスキングラフ
トメッシャー(ジンマー社製)を用いて拡大率1.5:
1のスリット状の大空隙(連通孔)を穿孔し、本発明の
異種空隙内包マトリックスを得た。Hereinafter, the present invention will be described in more detail with reference to examples. (Example 1) Preparation of gelatin matrix containing heterogeneous void-encapsulated collagen Preparation of gelatin-collagen solution Purified gelatin powder (manufactured by Nacalai Tesque) in phosphate buffer
Was dissolved to prepare a 5 w / v% gelatin solution. Atelocollagen adjusted to 1 w / v% (manufactured by Koken Co., Ltd.)
0.1% acidic solution at room temperature with RO water and sodium hydroxide to a final concentration of 0.5 w / v%, pH 7-7.
5 and the gelatin solution prepared above was mixed at a weight ratio of 5:
The mixture was mixed at a ratio of 1 and uniformly dispersed to obtain a gelatin-collagen solution. The gelatin-collagen solution prepared in Preparation of the heterogeneous void inclusion matrix <400-200 type> is poured into an aluminum mold of 11 cm × 11 cm so that the gelatin / collage becomes 400 mg / collagen / 200 mg / mold and freeze-dried in vacuum. Thus, a matrix having small voids was obtained. The resulting matrix was subjected to a dry heat treatment at 180 ° C. for 1 hour to introduce crosslinking. Using a skin graft mesher (manufactured by Zimmer) for the matrix, an enlargement ratio of 1.5:
One slit-shaped large void (communication hole) was perforated to obtain a heterogeneous void inclusion matrix of the present invention.
【0027】(実施例2) 異種空隙内包マトリックス<発泡400-200タイプ>の作
製 RO水に精製ゼラチン粉末(ナカライテスク製)を溶解
し7.5w/v%ゼラチン溶液を調製した。37.5gの
1%アテロコラーゲン(株式会社高研製)の酸性溶液
を、室温下で水酸化ナトリウムを用いてpH7〜7.5
に調整し、上記で調製したゼラチン溶液を10g混合
し、最終濃度ゼラチン:1.5w/v%、コラーゲン:
0.75w/v%となるようRO水を加え、ゼラチン−コ
ラーゲン溶液を調製した。得られた混合溶液をホモジナ
イザーで氷冷下で5000rpmで3分間発泡させた後、
型あたりゼラチン:400mg、コラーゲン:200m
gとなるよう所定の形状の型に流し込み、実施例1に記
載の方法で凍結乾燥、熱処理および穿孔を行い異種空隙
内包マトリックスを得た。(Example 2) Preparation of heterogeneous void inclusion matrix <foam 400-200 type> Purified gelatin powder (manufactured by Nacalai Tesque) was dissolved in RO water to prepare a 7.5 w / v% gelatin solution. An acidic solution of 37.5 g of 1% atelocollagen (manufactured by Koken Co., Ltd.) was treated with sodium hydroxide at room temperature at pH 7 to 7.5.
And 10 g of the gelatin solution prepared above was mixed to a final concentration of gelatin: 1.5 w / v%, collagen:
RO water was added to a concentration of 0.75 w / v% to prepare a gelatin-collagen solution. After foaming the obtained mixed solution at 5000 rpm for 3 minutes under ice cooling with a homogenizer,
Gelatin per mold: 400 mg, collagen: 200 m
Then, the mixture was poured into a mold having a predetermined shape so as to obtain g, and lyophilized, heat-treated and perforated by the method described in Example 1 to obtain a heterogeneous void inclusion matrix.
【0028】(実施例3) 異種空隙内包マトリックス<発泡400-100タイプ>の作
製 18.75gの1%アテロコラーゲン(株式会社高研
製)の0.1%酸性溶液を原料として、最終濃度ゼラチ
ン:1.5w/v%、コラーゲン:0.375w/v%となる
ようにゼラチン−コラーゲン溶液を調製し、型あたりゼ
ラチン:400mg、コラーゲン:100mgとなるよ
う型に流し込む以外は実施例2と同様に異種空隙内包マ
トリックスを調製した。Example 3 Preparation of Heterogeneous Void Inclusion Matrix <Foam 400-100 Type> 18.75 g of a 0.1% acidic solution of 1% atelocollagen (manufactured by Koken Co., Ltd.) was used as a raw material, and the final concentration of gelatin was 1: 1. A gelatin-collagen solution was prepared so as to have a concentration of 0.5 w / v% and collagen: 0.375 w / v%, and different types were prepared in the same manner as in Example 2 except that the solution was poured into a mold so that the gelatin per mold was 400 mg and the collagen was 100 mg. A void inclusion matrix was prepared.
【0029】(実施例4) 異種空隙内包ゼラチンマトリックス<発泡ゼラチン>の
作製 pH7〜7.5、最終濃度1.5w/v%となるよう調製
したゼラチン溶液をホモジナイザーで氷冷下で5000
rpmで3分間発泡させた後、型あたりゼラチン:400
mgとなるよう所定の形状の型に流し込む以外は実施例
2と同様に異種空隙内包ゼラチンマトリックスを調製し
た。Example 4 Preparation of a Gelatin Matrix Encapsulating Different Kinds of Voids <Foamed Gelatin> A gelatin solution prepared to have a pH of 7 to 7.5 and a final concentration of 1.5 w / v% was cooled to 5000 by a homogenizer under ice-cooling.
After foaming for 3 minutes at rpm, gelatin per mold: 400
A heterogeneous void-encapsulating gelatin matrix was prepared in the same manner as in Example 2 except that the mixture was poured into a mold having a predetermined shape so as to obtain a mg.
【0030】(比較例1) 異種空隙内包コラーゲンマトリックス<発泡コラーゲン
>の作製 pH7〜7.5、最終濃度0.75w/v%となるよう調
製したコラーゲン溶液をホモジナイザーで氷冷下で50
00rpmで3分間発泡させる以外は、実施例4と同様に
して異種空隙内包コラーゲンマトリックスを調製した。Comparative Example 1 Preparation of Collagen Matrix Containing Heterogeneous Voids <Foamed Collagen> A collagen solution prepared to have a pH of 7 to 7.5 and a final concentration of 0.75 w / v% was cooled with an homogenizer under ice-cooling.
A heterogeneous void-encapsulated collagen matrix was prepared in the same manner as in Example 4, except that foaming was performed at 00 rpm for 3 minutes.
【0031】(実施例5) ラット皮膚欠損モデルにおける本発明品の肉芽造成促進
効果 本発明品の組織再生促進の作用を確認するために、ラッ
トの皮膚欠損モデルに適用して、特にその大空隙部にお
ける肉芽促進効果を検討した。Sprague-Dawley系雌性ラ
ット(200−300g)背部を剃毛し、3×3cmの皮筋を温
存した全層皮膚欠損創を正中線をはさんで左右対称に2
箇所、メスを利用して外科的に作製した。この皮筋温存
全層皮膚欠損創(以下、単に皮膚欠損創と略)に、実施
例1による<400-200タイプ>と、実施例2による<発
泡400-200タイプ>を3×3cmよりやや小さめにカット
して貼付した。今実験においては、スリット部分を拡張
して横幅を1.2〜1.5倍にして使用した。(Example 5) Granulogenesis-promoting effect of the product of the present invention in a rat skin defect model In order to confirm the effect of the product of the present invention on promoting tissue regeneration, it was applied to a rat skin defect model, and particularly its large voids. The granulation promotion effect in the part was examined. Sprague-Dawley female rats (200-300 g) were shaved on the back, and a full-thickness skin defect wound preserving 3 × 3 cm skin muscle was symmetrically placed across the midline.
It was surgically prepared using a scalpel. In this skin muscle-preserving full-thickness skin defect wound (hereinafter simply referred to as skin defect wound), the <400-200 type> according to Example 1 and the <foaming 400-200 type> according to Example 2 are slightly smaller than 3 × 3 cm. And pasted. In the present experiment, the width of the slit portion was expanded to 1.2 to 1.5 times for use.
【0032】貼付時には滲出液を効率よく吸収する現象
が見られた。貼付3日後には、いずれのマトリックスも
拡張時に形成された菱形の大空隙部に赤色の肉芽組織が
認められ始めたが、大空隙部周囲のマトリックスは貼付
時の状態を保ち残存していた。貼付7日後にはそれぞれ
マトリックスの上辺の位置に肉芽が達した。貼付7日後
で屠殺し解剖して皮膚欠損創部分の皮膚組織標本を作製
し、組織形成状態を確認したところ、どちらのマトリッ
クスも、大空隙部に毛細血管や、線維芽細胞などの組織
再生を促進させる細胞が多数集中し、この大空隙部を起
点としてマトリックスの小空隙部に血管や細胞が侵入し
ている様子が観察された。この結果から、実施例1によ
る<400-200タイプ>と、実施例2による<発泡400-200
タイプ>は、本発明の目的とする組織再生促進を、大空
隙部を足がかりとする肉芽造成によって達成しているこ
とが確認された。また、小空隙を得る手段としての凍結
乾燥品とあらかじめ発泡させたものとの間では差異を認
めなかった。At the time of application, a phenomenon was observed in which exudate was efficiently absorbed. Three days after application, red granulation tissue began to be observed in the large diamond-shaped voids formed during the expansion of each matrix, but the matrix around the large voids remained in the state at the time of application and remained. Seven days after application, granulation reached the upper side of the matrix. Seven days after application, the tissue was sacrificed and dissected to prepare a skin tissue specimen of the skin defect wound area, and the state of tissue formation was confirmed. Both matrices were found to regenerate tissues such as capillaries and fibroblasts in the large void. A large number of cells to be promoted were concentrated, and it was observed that blood vessels and cells had invaded the small voids of the matrix starting from the large voids. From these results, the <400-200 type> according to Example 1 and the <foaming 400-200 type> according to Example 2
Type>, it was confirmed that promotion of tissue regeneration, which is the object of the present invention, was achieved by granulation with a large void as a foothold. Also, no difference was observed between the freeze-dried product as a means for obtaining small voids and the foamed product in advance.
【0033】(実施例6) 本発明品の構成品がラット皮膚欠損モデルの肉芽造成へ
与える影響 本発明品の構成品が組織再生促進に与える影響を確認す
るために、上述のラットの皮膚欠損モデルを利用して、
肉芽促進効果を検討した。本検討では、ゼラチン単独体
である実施例4の<発泡ゼラチン>、コラーゲン単独で
ある比較例1の<発泡コラーゲン>、ゼラチンとコラー
ゲンの複合体である実施例2の<発泡400-200タイプ
>、を比較検討した。ゼラチンは単純に凍結乾燥させる
と効果的に小空隙を持つスポンジを作りにくいため、あ
らかじめ発泡させた実施例4による<発泡ゼラチン>を
利用した。他のものも、全て同様に発泡体を利用した。
実施例5の方法に従って、ラットの皮膚欠損創に上記<
発泡ゼラチン>、<発泡コラーゲン>、<発泡400-200
タイプ>を貼付し、経過観察および皮膚組織標本を作製
して検討した。<発泡400-200タイプ>の結果は実施例
5の通りであった。<発泡ゼラチン>は、貼付3日後、
大空隙部周囲のマトリックスは残存を保っていたが、<
発泡400-200タイプ>に対して薄層化、拡張などの変形
を来していた。貼付7日後には大空隙部に肉芽が形成さ
れたが、上辺よりやや下方にとどまった。貼付7日後の
組織形成状態は、大空隙部に毛細血管・線維芽細胞など
の細胞が多数集中していたが、マトリックスの小空隙部
への血管や細胞の侵入は<発泡400-200タイプ>にやや
劣っていた。ただし、今発明の目的である組織再生促進
はある程度達成しているものと見なされた。<発泡コラ
ーゲン>は貼付3日後では大空隙部の辺縁が不明瞭であ
った。貼付7日後の大空隙部への肉芽形成も不良であっ
た。貼付7日後の組織形成状態は、大空隙部の画然たる
形成が不良であって血管・細胞も散漫な分散であり、肉
芽も量的に造成されておらず、マトリックスの小空隙部
への血管や細胞の侵入も他の2タイプに比して劣ってい
た。このことから、<発泡コラーゲン>は、今回の目的
にはそぐわないものと見なされた。(Example 6) Effect of the components of the present invention on granulation in a rat skin defect model In order to confirm the effects of the components of the present invention on promoting tissue regeneration, the above-mentioned rat skin defect was examined. Using the model,
The granulation promoting effect was examined. In this study, <foamed gelatin> of Example 4 which is a single body of gelatin, <foamed collagen> of Comparative Example 1 which is a collagen alone, and <foamed 400-200 type> of Example 2 which is a complex of gelatin and collagen. Were compared. Since it is difficult to effectively produce a sponge having small voids by simply freeze-drying gelatin, <foamed gelatin> according to Example 4 which had been foamed in advance was used. All others similarly utilized foam.
According to the method of Example 5, the above-mentioned <
Expanded gelatin>, <Expanded collagen>, <Expanded 400-200
Type> was affixed, followed by observation and preparation of a skin tissue specimen. The result of <foaming 400-200 type> was as in Example 5. <Foamed gelatin>
The matrix around the large void remained, but <
Foaming 400-200 type> was deformed such as thinning and expansion. Seven days after the application, granulation was formed in the large void portion, but remained slightly below the upper side. The tissue formation state 7 days after application was such that a large number of cells such as capillaries and fibroblasts were concentrated in the large voids, but the invasion of blood vessels and cells into the small voids of the matrix was <foaming 400-200 type>. It was slightly inferior. However, the promotion of tissue regeneration, which is the object of the present invention, was considered to have been achieved to some extent. In <foamed collagen>, the edge of the large void was unclear three days after application. The formation of granulation in the large void 7 days after application was also poor. The tissue formation state 7 days after application is that the large voids are not clearly formed, the blood vessels and cells are diffusely dispersed, the granulation is not formed quantitatively, and the matrix is not spread into the small voids. Invasion of blood vessels and cells was also inferior to the other two types. From this, <foamed collagen> was deemed to be unsuitable for this purpose.
【0034】(実施例7) 本発明品の構成比がラット皮膚欠損モデルの肉芽造成へ
与える影響 本発明品の構成品の中心であるゼラチンとコラーゲンの
比率が組織再生促進に与える影響を確認するために、2
種類の構成比について、上述のラットの皮膚欠損モデル
を利用して、肉芽促進効果を検討した。本検討では、実
施例2の<発泡400-200タイプ>およびゼラチンに対し
てコラーゲン比をより減らした実施例3の<発泡400-10
0タイプ>、を比較検討した。<発泡400-200タイプ>の
結果は実施例5の如くであった。<発泡400-100タイプ
>の結果は、実施例5の<発泡400-200タイプ>の結果
とほぼ等価であった。このことと、実施例6の結果か
ら、ゼラチンにはコラーゲンが少なくとも混合された状
態であることが望ましい結果を得られると判断された。(Example 7) Effect of the composition ratio of the product of the present invention on granulation formation in a rat skin defect model The effect of the ratio of gelatin and collagen, which are the main components of the product of the present invention, on promotion of tissue regeneration will be confirmed. For 2
With respect to the composition ratio of the types, the granulation promoting effect was examined using the rat skin defect model described above. In the present study, the <foaming 400-200 type> of Example 2 and the <foaming 400-10 type> of Example 3 in which the collagen ratio was further reduced with respect to gelatin.
0 type> was compared. The result of <foaming 400-200 type> was as in Example 5. The result of <foaming 400-100 type> was almost equivalent to the result of <foaming 400-200 type> of Example 5. From this and the results of Example 6, it was determined that it was possible to obtain the desired result that gelatin was at least mixed with collagen.
【0035】(実施例8) 本発明品の構成が生分解性材料である必要性の検討 実施例2の<発泡400-200タイプ>と比較して、生分解
性でない市販の発泡ポリウレタンスポンジにジンマー・
スキングラフトメッシャーを用いて拡大率1.5:1の
スリット状の連通孔を穿孔して大空隙部とした<ウレタ
ンスポンジ>の評価を実施例5に即して実験的に検討し
た。<発泡400-200タイプ>の短期評価結果は実施例5
の如くである。1ヶ月後には組織は肉芽で埋め尽くさ
れ、原初のマトリックスは完全に消滅した。<ウレタン
スポンジ>では、貼付3日後では皮膚欠損創と密着して
おり大空隙部周辺のマトリックスは全く不変であったが
滲出液はよく吸収していた。貼付7日後の組織では大空
隙部に血管、細胞の侵入が認められた。1ヶ月後には小
空隙部も血管・細胞に埋め尽くされ、肉芽も生じたが、
原初のマトリックスは完全に残存していて損傷面と固着
しており、異物反応も盛んであった。このことから、生
分解性でない<ウレタンスポンジ>の様なものは、肉芽
は造成しても、損傷組織を修復する意味での組織再生に
は役に立たないことが判明した。(Example 8) Examination of the necessity of the constitution of the product of the present invention as a biodegradable material Compared with the <foamed 400-200 type> of Example 2, a commercially available foamed polyurethane sponge which is not biodegradable was used. Zimmer
Using a skin graft mesher, the evaluation of <urethane sponge> which is a large void formed by perforating a slit-shaped communication hole having a magnification of 1.5: 1 was experimentally examined in accordance with Example 5. The short-term evaluation result of <Foam 400-200 type> is Example 5.
It is like. After a month, the tissue was full of granulation and the original matrix had completely disappeared. In the <urethane sponge>, 3 days after application, the matrix around the large void was completely intact with the skin defect wound, but the exudate was well absorbed. In the tissue 7 days after application, invasion of blood vessels and cells was observed in the large void. One month later, the small voids were filled with blood vessels and cells, and granulation occurred.
The original matrix was completely left and adhered to the damaged surface, and the foreign body reaction was active. From this, it was found that non-biodegradable materials such as <urethane sponge> are not useful for tissue regeneration in the sense of repairing damaged tissue even if granulation is formed.
【0036】(実施例9) 本発明品の大小空隙部を有する構造が肉芽形成を誘引す
るメカニズムの検討 <400-200タイプ>・<発泡400-200タイプ>・<発泡40
0-100タイプ>の(Example 9) Examination of the mechanism by which the structure of the present invention having large and small voids induces granulation formation <400-200 type>, <foamed 400-200 type>, <foamed 40
0-100 type>
【実施例5】の方法による貼付7日後の組織標本を、糖
を染色するアルシアンブルー・PAS染色法で染色し
た。<400-200タイプ>・<発泡400-200タイプ>・<発
泡400-100タイプ>は調製時に糖を含まないで作製され
ることから、糖に染色された部分は生体成分(滲出液な
ど)が浸透した結果と見なされる。いずれの標本におい
ても、大空隙部から派生して、マトリックス部分の小空
隙部をたどるような形でマトリックス内部まで糖が染色
され、大空隙部から滲出液などの成分が小空隙部まで効
率的に浸透している状態が確認された。多数の小空隙部
内に連通して大空隙が存在している形状がこれら滲出液
などの有用物質の浸透を促し、血管・細胞などの侵入を
促進させることが示唆された。The tissue specimen 7 days after application according to the method of Example 5 was stained with Alcian Blue / PAS staining method for staining sugar. The <400-200 type>, <foamed 400-200 type>, and <foamed 400-100 type> are made without sugar at the time of preparation, so the part stained with sugar is a biological component (exudate, etc.) Is considered to be the result of infiltration. In all specimens, sugars are stained inside the matrix in a manner that follows the small voids in the matrix part, deriving from the large voids, and components such as exudate from the large voids are efficiently transferred to the small voids It was confirmed that it had penetrated into the water. It has been suggested that the shape in which the large voids are communicated with the many small voids promotes the penetration of useful substances such as exudates and the invasion of blood vessels and cells.
【0037】(実施例10) 本発明品が最終滅菌としてEOG滅菌可能な材料であるこ
との検討 最終滅菌として局方に基づく湿式EOG滅菌を実施する以
外は、実施例1の<400-200タイプ>と同様にして異種
空隙内包コラーゲンマトリックスを調製した。実施例5
の方法に従って、ラットの皮膚欠損創に上記を貼付し、
経過観察および皮膚組織標本を作製して検討した。上記
実施例10の180℃1時間熱処理−EOG滅菌マトリッ
クスは実施例1の<400-200タイプ>マトリックスと同
様に貼付3日後の大空隙部周囲のマトリックス残存が良
好であった。貼付7日後の大空隙部への肉芽形成も良好
であった。(Example 10) Examination that the product of the present invention is a material that can be subjected to EOG sterilization as final sterilization Except for performing wet EOG sterilization based on the Pharmacopoeia as the final sterilization, the <400-200 type of Example 1 is used. >, A heterogeneous void-encapsulated collagen matrix was prepared. Example 5
According to the method described above, the above is attached to the skin defect wound of the rat,
Follow-up observations and skin tissue specimens were prepared and examined. In the same manner as the <400-200 type> matrix of Example 1, the matrix treated at 180 ° C. for 1 hour and treated with EOG in Example 10 had good residual matrix around large voids 3 days after application. The formation of granulation in the large voids 7 days after application was also good.
【0038】(実施例11) 本発明品が最終滅菌としてγ線滅菌可能な材料であるこ
との検討 乾熱処理を180℃で3時間行い、最終滅菌として25
kGyのγ線を照射する以外は、実施例1の<400-200
タイプ>と同様にして異種空隙内包コラーゲンマトリッ
クスを調製した。実施例5の方法に従って、ラットの皮
膚欠損創に上記を貼付し、経過観察および皮膚組織標本
を作製して検討した。上記実施例11の180℃3時間
熱処理−γ線滅菌マトリックスは実施例1の<400-200
タイプ>マトリックスと同様に貼付3日後の大空隙部周
囲のマトリックス残存が良好であった。貼付7日後の大
空隙部への肉芽形成も良好であった。(Example 11) Examination that the product of the present invention is a material which can be sterilized by γ-ray as final sterilization Dry heat treatment is performed at 180 ° C for 3 hours, and final sterilization is performed at 25 ° C.
<400-200 of Example 1 except that kGy γ-rays were irradiated.
Type>, a heterogeneous void-encapsulated collagen matrix was prepared. According to the method of Example 5, the above was applied to a skin defect wound of a rat, followed by follow-up observation and preparation of a skin tissue specimen, and examined. The heat treatment at 180 ° C. for 3 hours and the γ-ray sterilization matrix of Example 11 are the same as those of Example 1 <400-200.
As in the case of Type> Matrix, the matrix remained around the large void portion 3 days after application was good. The formation of granulation in the large voids 7 days after application was also good.
【0039】[0039]
【発明の効果】以上に詳述したように本発明は、大空隙
部と、大空隙部数に比して多数の小空隙部を有する生体
分解性材料で構成される多孔質マトリックスを肉芽造成
用被覆材料として用いるので糖尿病性潰瘍、褥瘡などの
難治性潰瘍の治療に用いた場合、滲出液を貯留させず
に、損傷面に肉芽を造成し、頻回の追加処置で目的達成
でき、目的達成後の除去を行うことなく肉芽を造成でき
る。また、コスト的にも安価で治療に有効な材料が提供
できる。更に、本発明の肉芽造成用被覆材料は治療に有
効な物質を患者自身の滲出液から得て有効活用できるの
で治療効果が格段に向上する。As described in detail above, the present invention provides a porous matrix composed of a biodegradable material having large voids and a large number of small voids compared to the number of large voids for granulation. When used for the treatment of intractable ulcers such as diabetic ulcers and pressure ulcers, it can be used as a coating material to create granulation on the damaged surface without accumulating exudate. Granulation can be created without subsequent removal. In addition, a material that is inexpensive and effective for treatment can be provided. Furthermore, the coating material for granulation of the present invention can obtain a therapeutically effective substance from the patient's own exudate and can utilize it effectively, so that the therapeutic effect is significantly improved.
【0040】本発明の肉芽造成用被覆材料は、損傷表面
側に開口した大空隙部により滲出液の吸収を促進しつつ
大小の空隙部に効率よく自己体液(滲出液、血液を含
む)中の必要物質を吸着して利用することによって、大
空隙部中に積極的に毛細血管・細胞を誘引して肉芽造成
を促し、その結果波及的に小空隙に毛細血管・細胞を伸
展させて肉芽生体組織を速やかに再構築させることによ
り優れた効果を発揮する。The coating material for granulation of the present invention promotes the absorption of exudate by the large voids opened to the damaged surface side, while efficiently excreting autologous body fluids (including exudate and blood) in large and small voids. By adsorbing and using the necessary substances, it actively attracts capillaries and cells into the large voids and promotes granulation, resulting in the spread of the capillaries and cells into the small voids and the granulation organism. It has excellent effects by quickly restructuring the organization.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 石川 啓司 神奈川県足柄上郡中井町井ノ口1500番地 テルモ株式会社内 (72)発明者 小西 淳 神奈川県足柄上郡中井町井ノ口1500番地 テルモ株式会社内 Fターム(参考) 4C081 AA12 AB19 BA16 CA151 CA171 CD011 CD121 CD151 DA02 DB03 DC12 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Keiji Ishikawa 1500 Inoguchi, Nakai-machi, Ashigara-kami, Kanagawa Prefecture Inside Terumo Corporation (72) Inventor Jun Konishi 1500 Inoguchi, Nakai-machi, Ashigara-gun, Kanagawa Prefecture Terumo Corporation F-term (reference) 4C081 AA12 AB19 BA16 CA151 CA171 CD011 CD121 CD151 DA02 DB03 DC12
Claims (6)
空隙部を有する生体分解性材料で構成される多孔質マト
リックスからなる肉芽造成用被覆材料。A coating material for granulation comprising a porous matrix composed of a biodegradable material having a large void portion and a large number of small void portions compared to the number of large void portions.
隙部は少なくとも多孔質マトリックスの厚さ以上の長径
を有し、更に大空隙部が多孔質マトリックス表面の少な
くとも一方に開口部を有している請求項1記載の肉芽造
成用被覆材料。2. The large void portion has a slit shape, the large void portion has a longer diameter than at least the thickness of the porous matrix, and the large void portion has an opening in at least one of the surfaces of the porous matrix. The coating material for granulation construction according to claim 1 which has.
柱の形状を有し、更に該大空隙部が多孔質マトリックス
表面の少なくとも一方に開口部を有している請求項1記
載の肉芽造成用被覆材料。3. The large gap portion according to claim 1, wherein said large gap portion has a shape of a cylinder, an elliptic cylinder or a quadrangular prism, and said large gap portion has an opening in at least one of the surfaces of the porous matrix. Coating material for granulation.
トリックスの厚さ以下である請求項1〜3のいずれか1
項に記載の肉芽造成用被覆材料。4. The method according to claim 1, wherein the diameter of the small gap is not less than 5 μm and not more than the thickness of the porous matrix.
Item 10. The coating material for forming granulation according to item 8.
ゲン、糖類、ポリ乳酸またはポリグリコール酸を単独ま
たは混合したもので構成されている請求項1〜4のいず
れか1項に記載の肉芽造成用被覆材料。5. The granulation method according to claim 1, wherein the biodegradable material is composed of gelatin, collagen, saccharide, polylactic acid or polyglycolic acid alone or in a mixture. For coating material.
ゲンを混合したもので構成されている請求項5に記載の
肉芽造成用被覆材料。6. The coating material according to claim 5, wherein the biodegradable material is composed of a mixture of gelatin and collagen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000186646A JP2002000716A (en) | 2000-06-21 | 2000-06-21 | Covering material for granulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000186646A JP2002000716A (en) | 2000-06-21 | 2000-06-21 | Covering material for granulation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002000716A true JP2002000716A (en) | 2002-01-08 |
Family
ID=18686770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000186646A Pending JP2002000716A (en) | 2000-06-21 | 2000-06-21 | Covering material for granulation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2002000716A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009515919A (en) * | 2005-11-17 | 2009-04-16 | ゲリタ アクチェンゲゼルシャフト | Angiogenesis promotion substrate |
-
2000
- 2000-06-21 JP JP2000186646A patent/JP2002000716A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009515919A (en) * | 2005-11-17 | 2009-04-16 | ゲリタ アクチェンゲゼルシャフト | Angiogenesis promotion substrate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10653810B2 (en) | Ready to use biodegradable and biocompatible device and a method of preparation thereof | |
EP1259269B1 (en) | Agent for the treatment of wounds | |
Chopra et al. | Strategies and therapies for wound healing: a review | |
JP2719671B2 (en) | Wound dressing | |
DE68915540T2 (en) | FOR CELL-PULLABLE MEDICAL MATERIAL AND ARTIFICIAL SKIN. | |
CA2132368A1 (en) | Wound implant materials | |
WO1999064655A1 (en) | Collagen material and process for producing the same | |
WO1998022155A1 (en) | Artificial neural canal | |
US10046088B2 (en) | Nanoscale collagen particles and membranes | |
CN107073172B (en) | Porous foams derived from extracellular matrix, porous foam ECM medical devices, and methods of use and manufacture thereof | |
JP2024123220A (en) | Controlled hydrogel delivery of focal adhesion kinase inhibitors to reduce scar formation | |
JP2009506811A (en) | Shaped body for medical treatment of wounds | |
JPH08506497A (en) | Pharmaceutical composition comprising a sponge-like material consisting of an ester derivative of hyaluronic acid in combination with other pharmaceutically active substances | |
WO2017100878A1 (en) | Process for producing asymmetric membranes, membranes thus produced and use thereof | |
KR20210122242A (en) | Biological scaffolds and methods of making them | |
ES2323126T3 (en) | HEMOSTATIC AGENT CONTAINING POLYVINYL ALCOHOL AND ITS AVAILABLE FOR MEDICINE. | |
WO1989008466A1 (en) | Medical material permitting cells to enter thereinto and artificial skin | |
JPS62246370A (en) | Wound covering material | |
JP2002000716A (en) | Covering material for granulation | |
KR100546793B1 (en) | Foam dressing using chitosan and its manufacturing method | |
JP2008525112A (en) | Antimicrobial barriers, systems and methods formed from hydrophilic polymer structures such as chitosan | |
JPH05192363A (en) | Wound covering material | |
JPH08196618A (en) | Cell invasive collagen formulation, artificial skin and their manufacture | |
Mustafa et al. | Chitosan applications used in medical therapy of tissue regeneration | |
RU2800928C2 (en) | Implant containing collagen membrane |